Effect of cyclooxygenase inhibitors in a xenograft model of canine mammary tumours

被引:9
作者
Sonzogni-Desautels, K. [1 ]
Knapp, D. W. [2 ]
Sartin, E. [3 ]
Dore, M. [1 ]
机构
[1] Univ Montreal, Fac Med Vet, Dept Pathol & Microbiol, St Hyacinthe, PQ J2S 7C6, Canada
[2] Purdue Univ, Sch Vet Med, Dept Vet Clin Sci, W Lafayette, IN 47907 USA
[3] Auburn Univ, Coll Vet Med, Dept Pathobiol, Auburn, AL 36849 USA
基金
加拿大自然科学与工程研究理事会;
关键词
COX-2; deracoxib; dogs; mammary cancer; piroxicam; prostaglandins; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; BREAST-CANCER INCIDENCE; URINARY-BLADDER CANCER; PROSTAGLANDIN E-2; COX-2; EXPRESSION; ASPIRIN USE; CELL-LINES; IN-VITRO; PIROXICAM; COLON;
D O I
10.1111/j.1476-5829.2010.00242.x
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Inhibition of cyclooxygenase-2 (COX-2) represents a possible avenue for the prevention and/or treatment of some cancers. Our goal was to compare the effect of a selective inhibitor of COX-2, deracoxib, and a COX-1 and -2 inhibitor, piroxicam, on the growth of canine mammary tumours in a murine model. CMT-9 was used to induce xenografts in nude mice. Mice were treated with piroxicam (0.6 mg kg(-1)), deracoxib (6 mg kg(-1)) or a control solution. Tumour volumes between 0 and 24 days post-treatment showed no significant difference between all groups. A second series of experiments was performed with a higher dose of piroxicam (0.9 mg kg(-1)). Tumour volumes between 14 and 21 days post-treatment were significantly smaller in piroxicam-treated mice compared with controls. These results demonstrate that COX inhibition reduced the growth of canine mammary cancer xenografts in mice, suggesting that COX inhibitors could have a positive effect in dogs.
引用
收藏
页码:161 / 171
页数:11
相关论文
共 64 条
  • [21] Cyclooxygenase-5: a target for the prevention and treatment of breast cancer
    Howe, LR
    Subbaramaiah, K
    Brown, AMC
    Dannenberg, AJ
    [J]. ENDOCRINE-RELATED CANCER, 2001, 8 (02) : 97 - 114
  • [22] COX-2 inhibitors for the prevention of breast cancer
    Howe, LR
    Dannenberg, AJ
    [J]. JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 2003, 8 (01) : 31 - 43
  • [23] Jacobs EJ, 2005, CANCER EPIDEM BIOMAR, V14, P261
  • [24] Johnson TW, 2002, CANCER EPIDEM BIOMAR, V11, P1586
  • [25] Cyclo-oxygenase isoenzymes: physiological and pharmacological role
    Kam, PCA
    See, AUL
    [J]. ANAESTHESIA, 2000, 55 (05) : 442 - 449
  • [26] KARGMAN SL, 1995, CANCER RES, V55, P2556
  • [27] Expression of cyclooxygenase-2 in canine renal cell carcinoma
    Khan, KNM
    Stanfield, KM
    Trajkovic, D
    Knapp, DW
    [J]. VETERINARY PATHOLOGY, 2001, 38 (01) : 116 - 119
  • [28] PHASE-I TRIAL OF PIROXICAM IN 62 DOGS BEARING NATURALLY-OCCURRING TUMORS
    KNAPP, DW
    RICHARDSON, RC
    BOTTOMS, GD
    TECLAW, R
    CHAN, TCK
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1992, 29 (03) : 214 - 218
  • [29] The in vitro effects of piroxicam and meloxicam on canine cell lines
    Knottenbelt, C
    Chambers, G
    Gault, E
    Argyle, DJ
    [J]. JOURNAL OF SMALL ANIMAL PRACTICE, 2006, 47 (01) : 14 - 20
  • [30] Colorectal cancer risk, chronic illnesses, operations and medications: case-control results from the Melbourne Colorectal Cancer Study (Reprinted from Cancer Research, vol 48, pg 4399-404, 1988)
    Kune, Gabriel A.
    Kune, Susan
    Watson, Lyndsey F.
    [J]. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2007, 36 (05) : 951 - 957